[go: up one dir, main page]

PE20211069A1 - Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina - Google Patents

Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina

Info

Publication number
PE20211069A1
PE20211069A1 PE2021000265A PE2021000265A PE20211069A1 PE 20211069 A1 PE20211069 A1 PE 20211069A1 PE 2021000265 A PE2021000265 A PE 2021000265A PE 2021000265 A PE2021000265 A PE 2021000265A PE 20211069 A1 PE20211069 A1 PE 20211069A1
Authority
PE
Peru
Prior art keywords
glutamyl
methylseelenoadenosine
selenoadenosyl
methylselenocysteine
homocystein
Prior art date
Application number
PE2021000265A
Other languages
English (en)
Inventor
Ronan Power
Zi-Jian Lan
Original Assignee
Alltech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Inc filed Critical Alltech Inc
Publication of PE20211069A1 publication Critical patent/PE20211069A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)

Abstract

Referida a una composicion que comprende la combinacion de compuestos de selenio, seleccionados de 5'-Metilselenoadenosina, Se-adenosil-L-homocisteina y Gamma-glutamil-metilseleno-cisteina; en una proporcion de 1: 1: 1; y un agente terapeutico para modular la glucosa seleccionado entre insulina, Aspart, Glulisina, LisPro, insulina NPH, entre otros; para modular el metabolismo de glucosa en un sujeto.
PE2021000265A 2014-03-14 2016-09-05 Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina PE20211069A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2014/029542 WO2015137983A1 (en) 2014-03-14 2014-03-14 Compositions of selenoorganic compounds and methods of use thereof
US14/855,128 US9642874B2 (en) 2014-03-14 2015-09-15 Compositions of selenoorganic compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20211069A1 true PE20211069A1 (es) 2021-06-09

Family

ID=54072241

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000265A PE20211069A1 (es) 2014-03-14 2016-09-05 Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina

Country Status (17)

Country Link
US (3) US10201559B2 (es)
EP (1) EP3116511B1 (es)
JP (2) JP6313479B2 (es)
KR (3) KR102448455B1 (es)
CN (3) CN106456658A (es)
AU (4) AU2014386236B2 (es)
BR (1) BR112016020233B1 (es)
CA (1) CA2940283C (es)
DK (2) DK3116511T3 (es)
HU (2) HUE051713T2 (es)
IL (1) IL247312A0 (es)
MX (2) MX2016011897A (es)
NZ (1) NZ723402A (es)
PE (1) PE20211069A1 (es)
PT (1) PT3116511T (es)
RU (2) RU2665135C2 (es)
WO (2) WO2015137983A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015137983A1 (en) 2014-03-14 2015-09-17 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
WO2016160594A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
KR102054640B1 (ko) * 2015-09-24 2019-12-11 서울대학교산학협력단 아데노신 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2017160678A1 (en) * 2016-03-14 2017-09-21 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
SG11201909932YA (en) 2017-05-19 2019-11-28 Alltech Inc Pharmaceutical agents, compositions, and methods relating thereto
JP7312184B2 (ja) 2017-10-23 2023-07-20 エピトラッカー インコーポレイテッド 脂肪酸アナログおよび代謝症候群に関連する症状の処置におけるそれらの使用
WO2019093699A1 (ko) * 2017-11-09 2019-05-16 서울대학교 산학협력단 셀레노사마필린 a와 그 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
KR102083180B1 (ko) * 2017-11-09 2020-03-02 서울대학교산학협력단 셀레노사마필린 a와 그 유도체, 이의 제조방법, 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
CN108484690B (zh) * 2018-05-16 2021-04-30 新乡拓新药业股份有限公司 一种1,2,3-三-O-乙酰基-5-脱氧-β-D-核糖的制备方法
JP2021525249A (ja) 2018-05-23 2021-09-24 エピトラッカー インコーポレイテッドＥｐｉｔｒａｃｋｅｒ， Ｉｎｃ． 加齢及び長期性の質に関連する状態の診断及び治療のための組成物及び方法
WO2020146263A1 (en) * 2019-01-09 2020-07-16 Epitracker, Inc. Compositions and methods for diagnosis and treatment of neurodegenerative diseases
CN111543641A (zh) * 2020-04-27 2020-08-18 江苏惠利生物科技有限公司 一种提高l-硒-甲基硒代半胱氨酸稳定性以及生物利用率的方法
US20230277549A1 (en) * 2020-07-23 2023-09-07 Purdue Research Foundation Notch signaling inhibitors for treating obesity and metabolic disorders
CN116333302B (zh) * 2023-03-31 2024-09-10 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6752981B1 (en) 1999-09-08 2004-06-22 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
CA2747954C (en) 1999-12-03 2014-02-25 The Regents Of The University Of California Phosphonate compounds
AU784462B2 (en) 2000-03-31 2006-04-06 Purdue Research Foundation Phosphoramidate prodrugs
PT1509537E (pt) 2002-04-26 2007-11-02 Gilead Sciences Inc Acumulação celular de análogos de fosfonato de compostos inibidores da protease do vih e os próprios compostos
NZ536327A (en) 2002-05-13 2007-08-31 Metabasis Therapeutics Inc PMEA and PMPA cyclic producing synthesis
NZ536328A (en) 2002-05-13 2007-11-30 Metabasis Therapeutics Inc Novel phosphonic acid based prodrugs of PMEA and its analogues
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US20060093684A1 (en) 2004-10-28 2006-05-04 Iwao Takeda Seleniferous composition for producing antioxidase in vivo
JP2006151965A (ja) 2004-10-28 2006-06-15 Mi Tec:Kk セレン含有組成物及びその製法
WO2006071103A1 (en) * 2004-12-31 2006-07-06 Heonjoong Kang Organoselenium containing compounds and their use
US20060198906A1 (en) 2005-03-07 2006-09-07 Sami Labs Limited Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease
US20070077238A1 (en) 2005-10-04 2007-04-05 Teo Alex Y Production of organic and inorganic selenium compounds by lactic acid bacteria
US20080004255A1 (en) 2005-10-14 2008-01-03 Alltech, Inc. Methods and compositions for altering cell function
CA2524551C (en) * 2005-10-14 2014-12-16 Alltech, Inc. Use of selenium yeasts in the treatment of alzheimer's disease
TWI319708B (en) 2005-10-14 2010-01-21 Methods and compositions for altering cell fuction
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
CN101045048B (zh) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 线粒体营养素组合物的应用
WO2007127273A2 (en) * 2006-04-24 2007-11-08 Alltech, Inc. Methods and compositions for altering cell function
WO2009032057A2 (en) 2007-08-29 2009-03-12 Adam Lubin Method for the selective therapy of disease
WO2009026949A1 (en) * 2007-08-31 2009-03-05 Dsm Ip Assets B.V. 4-amidino benzylamines for cosmetic and/or dermatological use
WO2009066299A2 (en) * 2007-11-23 2009-05-28 Rappaport Family Institute For Research Use of haptoglobin genotyping in diagnosis and treatment of cardiovascular disease
CN101289495A (zh) * 2008-05-23 2008-10-22 浙江大学 含硒五肽化合物及其应用
WO2011047434A1 (en) * 2009-10-22 2011-04-28 Propanc Pty Ltd A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
JP5510302B2 (ja) * 2010-12-15 2014-06-04 トヨタ紡織株式会社 接続部材、その製造方法及び接続構造体
RU2605287C2 (ru) * 2011-04-01 2016-12-20 Иасомай АБ Новая комбинация, содержащая n-ацетил-l-цистеин, и ее применение
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
NL2010222C2 (en) * 2013-02-01 2014-08-04 Conradus Ghosal Gho Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells.
CN114533753A (zh) * 2013-03-15 2022-05-27 全技术公司 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
WO2015137983A1 (en) 2014-03-14 2015-09-17 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
US20160000136A1 (en) * 2014-07-02 2016-01-07 Hamilton Beach Brands, Inc. Juice Extractor
US20160090397A1 (en) 2014-09-30 2016-03-31 Northeastern University Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities

Also Published As

Publication number Publication date
US10201558B2 (en) 2019-02-12
RU2016136530A (ru) 2018-03-16
US9642874B2 (en) 2017-05-09
HUE056172T2 (hu) 2022-01-28
JP2017512828A (ja) 2017-05-25
IL247312A0 (en) 2016-09-29
US20160045533A1 (en) 2016-02-18
CN106822168A (zh) 2017-06-13
MX2016011898A (es) 2018-03-12
JP7009053B2 (ja) 2022-01-25
DK3144001T3 (da) 2021-11-15
EP3116511B1 (en) 2020-08-26
US20160082033A1 (en) 2016-03-24
US20160361338A1 (en) 2016-12-15
CN106822168B (zh) 2020-11-27
NZ723233A (en) 2020-10-30
KR102764247B1 (ko) 2025-02-07
RU2016133469A (ru) 2018-04-17
HUE051713T2 (hu) 2021-03-29
AU2014386236B2 (en) 2019-07-11
US10201559B2 (en) 2019-02-12
CN106456658A (zh) 2017-02-22
BR112016020233B1 (pt) 2022-07-19
AU2014386236A1 (en) 2016-09-01
EP3116511A4 (en) 2017-10-18
JP6313479B2 (ja) 2018-04-18
KR20160125989A (ko) 2016-11-01
NZ723402A (en) 2024-11-29
AU2022204588A1 (en) 2022-07-21
PT3116511T (pt) 2020-11-19
KR102466389B1 (ko) 2022-11-11
RU2665135C2 (ru) 2018-08-28
JP2017078056A (ja) 2017-04-27
RU2016136530A3 (es) 2019-11-25
CN113694074A (zh) 2021-11-26
EP3116511A1 (en) 2017-01-18
AU2019246818A1 (en) 2019-10-31
KR102448455B1 (ko) 2022-09-28
AU2016222315A1 (en) 2017-03-30
WO2017048253A1 (en) 2017-03-23
BR112016020233A2 (es) 2017-08-15
CA2940283A1 (en) 2015-09-17
MX2016011897A (es) 2017-04-27
BR102016021058A2 (pt) 2017-05-30
KR20170032862A (ko) 2017-03-23
AU2016222315B2 (en) 2022-08-04
AU2019246818B2 (en) 2021-02-25
KR20210104070A (ko) 2021-08-24
DK3116511T3 (da) 2020-11-23
WO2015137983A1 (en) 2015-09-17
CA2940283C (en) 2021-03-30
RU2731383C2 (ru) 2020-09-02

Similar Documents

Publication Publication Date Title
PE20211069A1 (es) Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX367241B (es) Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer.
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
NI201500118A (es) Imidazopiridazinas sustituidas
SV2017005515A (es) Formulaciones de polvo nasal para el tratamiento de la hipoglicemia
CO2017006898A2 (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2015003634A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
MX2016008977A (es) Formulaciones farmaceuticas de insulina aspart estabilizadas.
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX2018007933A (es) Metodo de tratamiento de mamifero, incluido el ser humano, contra cancer usando agotamiento de metionina y asparagina.
PE20191149A1 (es) Uso farmaceutico de una composicion que contiene pirfenidona de liberacion prolongada (pfd-lp) para la reversion y tratamiento de la esteatohepatitis humana (nafld/nash)
DOP2016000007A (es) Pirazolpiridinas sustituidas
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
MX2017015247A (es) Metodos y composiciones para modular la microbiota intestinal y para manejar el peso.
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
CL2016000397A1 (es) Tratamiento contra el cáncer
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
PE20121537A1 (es) Combinacion de teobromina con un descongestivo
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
MX2018008196A (es) Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional.
PE20170305A1 (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
MX2017007856A (es) Composicion para el cuidado bucal.